Thomson Reuters releases 2015 edition of annual Drugs to Watch report

The Intellectual Property and Science business of Thomson Reuters, the world's leader in intelligent information for businesses and professionals, today released the 2015 edition of its annual Drugs to Watch report. The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach more than $3 billion in sales by 2019. Thomson Reuters analysts utilized Cortellis^™ Competitive Intelligence—the pharmaceutical industry's leading source for drug pipeline, deals, patents, and company content—to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $ 1 billion+) by 2019.

The analysis spotlights the following 11 potential blockbusters, ranked by highest sales forecasts:

"This year's forecast identifies a substantial increase in the number of predicted blockbusters, inviting discussion around the current status of the blockbuster model," said Wendy Hamilton, global head of Life Sciences at Thomson Reuters. "As the pharmaceutical industry navigates constantly evolving revenue streams, this report serves as a valuable resource for identifying the therapies with the strongest sales potential."